RECRUITINGOBSERVATIONAL
Observation Study on Reducing the Risk of Liver Cancer Associated With Hepatitis B (Zhiyuan) Project.
About This Trial
This study is a multicenter, prospective, observational real-world study designed to investigate and analyze the current treatment patterns of chronic hepatitis B (CHB) across 200 hospitals in China. By comparing patient outcomes under different therapeutic regimens, it aims to provide high-quality evidence-based medical data to optimize CHB treatment strategies and follow-up protocols, ultimately contributing to the advancement of a functional cure for chronic hepatitis B.
Who May Be Eligible (Plain English)
Who May Qualify:
- 1.Chronic HBV infection (HBsAg-positive for ≥6 months); 2.Age ≥18 years; 3.Patients who, based on real-world clinical practice needs, are planned or currently receiving treatment with:Entecavir (ETV),Tenofovir disoproxil fumarate (TDF),Tenofovir alafenamide fumarate (TAF),Tenofovir amibufenamide (TMF) OR Pegylated interferon α-2b-naïve patients OR Patients re-initiating pegylated interferon α-2b therapy; 4.Written willing to sign a consent form obtained from the patient.
Who Should NOT Join This Trial:
- 1.Severe hepatic dysfunction or decompensated cirrhosis; 2.Concurrent participation in other clinical trials; 3.Hepatocellular carcinoma (HCC).
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* 1.Chronic HBV infection (HBsAg-positive for ≥6 months); 2.Age ≥18 years; 3.Patients who, based on real-world clinical practice needs, are planned or currently receiving treatment with:Entecavir (ETV),Tenofovir disoproxil fumarate (TDF),Tenofovir alafenamide fumarate (TAF),Tenofovir amibufenamide (TMF) OR Pegylated interferon α-2b-naïve patients OR Patients re-initiating pegylated interferon α-2b therapy; 4.Written informed consent obtained from the patient.
Exclusion Criteria:
* 1.Severe hepatic dysfunction or decompensated cirrhosis; 2.Concurrent participation in other clinical trials; 3.Hepatocellular carcinoma (HCC).
Treatments Being Tested
DRUG
ETV,TDF,TAF,TMF
treated with entecavir (ETV), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide fumarate (TAF), or tenofovir amibufenamide (TMF)
DRUG
Peginterferon α-2b injection
treated with Peginterferon α-2b injection
Locations (20)
Huaxian People's Hospital
Anyang, China
Linzhou City People's Hospital
Anyang, China
Neihuang County People's Hospital
Anyang, China
Tangyin County People's Hospital
Anyang, China
The Fifth People's Hospital of Anyang
Anyang, China
The First Affiliated Hospital of Xinxiang Medical University (Hua County Branch)
Anyang, China
Guangzhou First People's Hospital
Guangzhou, China
The First Affiliated Hospital of Jinan University (Guangzhou Overseas Chinese Hospital)
Guangzhou, China
Hebi Coal Mining Group General Hospital
Hebi, China
Hebi Infectious Disease Hospital
Hebi, China
Junxian County People's Hospital
Hebi, China
Bo'ai County People's Hospital
Jiaozuo, China
Mengzhou Hospital of Traditional Chinese Medicine
Jiaozuo, China
Qinyang People's Hospital
Jiaozuo, China
The Secend People's Hospital of Jiaozuo
Jiaozuo, China
The Third People's Hospital of Jiaozuo
Jiaozuo, China
Xiuwu People's Hospital
Jiaozuo, China
Wenxian People's Hospital
Jiayuguan, China
Jiyang County Hospital of Traditional Chinese Medicine
Jinan, China
Shandong Public Health Clinical Center
Jinan, China